Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.62
- Piotroski Score 2.00
- Grade Buy
- Symbol (MIST)
- Company Milestone Pharmaceuticals Inc.
- Price $1.70
- Changes Percentage (0%)
- Change -$0
- Day Low $1.68
- Day High $1.76
- Year High $3.52
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.25
- Trailing P/E Ratio -1.17
- Forward P/E Ratio -1.17
- P/E Growth -1.17
- Net Income $-59,685,000
Income Statement
Quarterly
Annual
Latest News of MIST
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Mister Spex Third Quarter 2024 Earnings: €0.47 loss per share (vs €0.28 loss in 3Q 2023)
The chart displays trailing 12-month figures. Mister Spex's revenue is projected to grow 2.6% annually for the next 3 years, lower than the German Specialty Retail industry's 5.8% forecast. Two warnin...
By Yahoo! Finance | 1 day ago -
6 Mistakes Gen Z Is Making When Saving For a House
Generation Z, aged 12-27, are eager to buy homes amidst a challenging housing market. Despite being tech-savvy, they should be cautious of impulsive decisions and verify information sources. Experts a...
By Yahoo! Finance | 2 days ago -
4 of the biggest mistakes experts see people make investing in gold
Gold is gaining popularity as an investment due to its ability to hedge against inflation and diversify portfolios. Experts recommend allocating 5-10% of your portfolio to gold to balance risk and ret...
By Business Insider | 2 days ago
